Shanghai Pharma buys U.S. Cardinal Health’s China business for $557 million

(Reuters) – Shanghai Pharmaceuticals Holding Co has agreed to buy Cardinal Health Inc’s China drug distribution business for $557 million, winning a highly competitive auction in a move that will greatly expand its presence nationwide.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply